Lessening the Impact of Fatigue in Inflammatory Rheumatic Diseases

Summary

Fatigue is common and disabling for most patients with inflammatory rheumatic disease. Therapies designed to improve physical activity and 'talking' treatments, which positively help patients change the way they think and behave, are both helpful in reducing the burden of the fatigue. However, few patients have access to these treatments in most health services. This situation results from the absence of standardised programmes and limited availability of relevant therapists.

The investigators aim to enhance access to fatigue alleviating physical activity and talking therapies by testing innovative,standardised and cost-effective approaches to treatment delivery.

The investigators will also use this opportunity to understand how to select the best treatment for a patient based on their individual profile and to better understand how these treatments actually work. This in turn may lead to more refined and effective therapies in the future.

Conditions

• Rheumatoid Arthritis
• Lupus Erythematosus, Systemic
• Axial Spondyloarthritis
• Psoriatic Arthritis
• Sjogren's Syndrome

Interventions

BEHAVIORAL

Usual Care

Information booklet on fatigue which represents usual care in almost all UK rheumatology centres

BEHAVIORAL

Cognitive behavioural approach

A talking therapy which explicitly aims to replace unhelpful beliefs and behaviours through the application of patient-centred strategies and behavioural activities

BEHAVIORAL

Personalised Exercise Programme

PEP is a graded exposure behaviour therapy which aims to gradually optimise patients levels of physical activity with view to modifying their altered perception of effort and ultimately reduce the severity and impact of fatigue.

Sponsors & Collaborators

• Versus Arthritis

  collaborator OTHER

• University of Aberdeen

  lead OTHER

Principal Investigators

• Gary Macfarlane, PhD · University of Aberdeen

• Neil Basu, MBChB, PhD · University of Glasgow

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Model

PARALLEL

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2017-09-05

Primary Completion

2020-11-02

Completion

2020-11-02

Countries

• United Kingdom

Study Locations